Larotrectinib in TRK fusion-positive cancers in adults and children
The selective TRK inhibitor larotrectinib shrank tumours in three quarters of patients with NTRK fusions across 17 different cancer types and ages from infancy to old age, leading to the first tumour-agnostic approval of a targeted drug.
Overview
Pooled analysis of 55 patients (adults and children) with TRK fusion-positive solid tumours across 17 tumour types from three phase 1 and 2 trials treated with larotrectinib.
Objective response was 75 percent by independent review with 71 percent of responses ongoing at one year, activity independent of tumour type, fusion partner or age, and mostly low-grade toxicity.
- Objective response 75 percent across 17 tumour types.
- 71 percent of responses ongoing at one year; 55 percent of patients progression-free at one year.
NTRK fusion testing is now recommended in lung and other cancers without a common driver, and larotrectinib or entrectinib is the standard treatment when a fusion is found.
- NTRK fusions are rare (under 1 percent) in lung cancer.
- Acquired resistance mutations in the kinase domain develop; repotrectinib addresses some.
Similar pages
not linked directly; found by shared links- Key paperTRIDENT-1: repotrectinib in ROS1 fusion-positive non-small-cell lung cancer
Shares NTRK fusion-positive non-small-cell lung cancer, New England Journal of Medicine.
- TrialNAVIGATE
Shares NTRK fusion-positive non-small-cell lung cancer, Larotrectinib.
- TargetNTRK
Shares NTRK fusion-positive non-small-cell lung cancer, Larotrectinib.
- TermGene fusion
Shares NTRK fusion-positive non-small-cell lung cancer, Larotrectinib.